Pertuzumab–Docetaxel–Trastuzumab regimen in HER2-positive metastatic breast cancer: Real-world data from India
Purpose: Dual human epidermal growth factor receptor 2 (HER2) blockade with pertuzumab and trastuzumab plus chemotherapy is the standard first-line treatment for HER2-positive metastatic breast cancer (BC), as per the CLEOPATRA trial. However, real-world data from low- and middle-income countries (L...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2026-01-01
|
| Col·lecció: | Cancer Treatment and Research Communications |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S2468294226001073 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|